TITLE

Transparency in drug regulation: Mirage or oasis?

AUTHOR(S)
Lexchin, Joel; Mintzes, Barbara
PUB. DATE
November 2004
SOURCE
CMAJ: Canadian Medical Association Journal;11/23/2004, Vol. 171 Issue 11, p1363
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Comments on the legal protection of information used to approve new drugs in Canada. Reason behind the legal protection of drug regulation data; Disadvantages of non-disclosure to the Canadian Therapeutic Products Directorate; Comparison between U.S. and Canadian drug approval policies.
ACCESSION #
15060913

 

Related Articles

  • Editorial: Drug Regulation and Drug Information--Who Should Do What to Whom? Avorn, Jerry // American Journal of Public Health;Jan1995, Vol. 85 Issue 1, p18 

    The article comments on issues regarding drug regulation and drug information in the U.S. In the middle of the century, the U.S. tried to distinguish among ingested chemicals to reconcile the demands of public health as well as the needs of specific patients. On the issue of drug control, the...

  • Preapproval Opportunities. Douglas, Natalie // Applied Clinical Trials;Jun2008, Vol. 17 Issue 6, p76 

    The article focuses on the issues concerning the preapproval access to drugs in the U.S. It states that the process can provide months and perhaps years of treatment when other therapeutic options have failed. Meanwhile, drug developers who are involved in these programs must also ensure strict...

  • THE ART AND LAW OF SUPPLEMENT LABELS.  // Consumer Reports;May2004, Vol. 69 Issue 5, p16 

    Comments on the law and promotion of dietary supplements in the U.S. Examples of ridiculous supplement labels; Provision of the 1994 Dietary Supplement Health and Education Act; Responsibility and authority of the Federal Trade Commission with regard to misleading labels.

  • Bitter pill to slowly swallow. Makholwa, Andile // Finweek;6/30/2011, p26 

    The article reports that pharmaceutical companies in South Africa are not happy with the way South Africa's Medicines Control Council (MCC) is taking time in approving dossiers despite previous attempts to help the regulatory body reduce its backlog. Listed companies Adcock Ingram Holdings and...

  • Pharmacists, Pharmacovigilance, Unapproved Indications and the TGA. Sansom, Lloyd // Journal of Pharmacy Practice & Research;Jun2010, Vol. 40 Issue 2, p88 

    The author discusses the use of unapproved medications in Australia's hospitals under so-called compassionate or early-access programs. The author comments on the challenges faced by patients using such medical therapies including prospects that such drugs may be withdrawn. Also noted are...

  • Drug policy reform - the opportunity presented by 'legal highs'. Meacher, Molly C. // Psychiatrist;8/ 1/2013, Vol. 37 Issue 8, p249 

    Summary Current UK policy on drugs does little to reduce the potential harms to young people using drugs and in some ways can exacerbate them. The dramatic increase in the number of new psychoactive substances available in the UK carries the risk of increasing those harms and demands a new...

  • 'Fast-track' drug approvals hit speed bumps in Japan. Sipp, Douglas // Nature Medicine;Sep2004, Vol. 10 Issue 9, p883 

    Reports on concerns about the growing tendency of the Japanese government to speed up drug approvals. Lawsuit filed by families of cancer patients against drug manufacturer AstraZeneca and the Japanese government; Criticism against the scientific basis for the approval of the drug Iressa; Denial...

  • COLONIZING THERAPEUTIC SPACE: THE OVERLOOKED SCIENCE OF DRUG HUSBANDRY.  // Nature Reviews Drug Discovery;Feb2004, Vol. 3 Issue 2, p101 

    Focuses on drug discovery and development. Number of new molecular entitles (drugs) given approval by the U.S. Food and Drug Administration (FDA) in 2003; View that drug discovery and development is being depicted to the public as dependent on new technologies, suggesting this obscures the hard...

  • Key Hatch-Waxman reforms per MMA legislation.  // Drug Store News;11/22/2004, Vol. 26 Issue 16, p30 

    Provides information about the Key Hatch-Waxman reforms according to the Medicare Prescription Drug Improvement and Modernization Act. Rules for filing an abbreviated new drug application; Terms for holder of a new drug application; Conditions for any abbreviated new drug application submitted.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics